.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2013 for a massive $43 b...
.On the heels of a phase 3 gain that failed to wow capitalists, Ironwood Pharmaceuticals is actually...
.Don't quit Monte Rosa Rehabs right now. The Boston-based biotech is enjoying after authorizing a ma...
.Accept to today's Chutes & Ladders, our summary of significant management hirings, shootings as ...
.Commemorating his company's upsized going public (IPO), Septerna CEO Jeffrey Finer rang the positio...
.AbbVie has come back to the source of its own antipsychotic giant Vraylar seeking one more runaway ...
.GenSight Biologics is actually full weeks far from running out of loan. Once more. The biotech mere...
.Monopar Rehabs is bouncing back a medication coming from the scrap heap of AstraZeneca's rare illne...
.Along with new data out on Arcus Biosciences' speculative HIF-2a inhibitor, one group of analysts w...
.After developing a genetics treatment alliance along with Dyno Therapies in 2020, Roche is actually...
.Lundbeck is actually slashing guide market value of its own $250 thousand Abide Therapeutics acquis...
.The integration of real-world records (RWD) right into procedure feasibility as well as website ass...
.At this year's Intense Biotech Summit in Boston ma, our company caught up with innovators in the bi...
.Merck & Co. is actually setting down $30 million beforehand to get Yale spinout Modifi Bioscienc...
.Alpha-9 Oncology has actually raised a $175 million set C cycle to money its own clinical-stage rad...
.Eye medication maker Ocuphire Pharma is obtaining genetics therapy creator Opus Genes in an all-sto...
.Roche's chronic coughing course has actually faltered to a standstill. The drugmaker, which axed th...
.Gilead Sciences and also Merck & Co. have actually guided their once-weekly HIV mixture therapy ...
.Lykos Therapeutics may have shed three-quarters of its own staff following the FDA's denial of its ...
.Septerna might be actually as yet to reveal "any type of relevant clinical data," yet the biotech p...